Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;65(11):1160-1162.
doi: 10.1007/s00108-024-01756-6. Epub 2024 Sep 24.

[Malaria vaccination for national vaccination programs]

[Article in German]
Jürgen May  1   2 , Michael Ramharter  3   4 , Sirka Nitschmann  5
Affiliations

[Malaria vaccination for national vaccination programs]

[Article in German]
Jürgen May et al. Inn Med (Heidelb). 2024 Nov.
No abstract available

PubMed Disclaimer

References

Literatur

    1. WHO (2023) World Malaria Report 2023. World Health Organization, Geneva
    1. RTS,S Clinical Trials Partnership (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386:31–45 - DOI
    1. WHO WHO recommends groundbreaking malaria vaccine for children at risk: historic RTS,S/AS01 recommendation can reinvigorate the fight against malaria. https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-m... at-risk (Erstellt: 6. Okt. 2021). Zugegriffen: 1. Juni 2024
    1. WHO Malaria: the malaria vaccine implementation programme. https://www.who.int/news-room/questions-and-answers/item/malaria-vaccine... (Erstellt: 2. März 2020). Zugegriffen: 1. Juni 2024
    1. Sang S, Datoo MS, Otieno E, Muiruri C, Bellamy D, Gathuri E, Ngoto O, Musembi J, Provstgaard-Morys S, Stockdale L, Aboagye J, Woods D, Lawrie A, Roberts R, Keter K, Kimani D, Ndungu F, Kapulu M, Njau I, Orindi B, Ewer KJ, Hill AVS, Bejon P, Hamaluba M (2023) Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya. Wellcome Open Res 8:450 - DOI - PubMed - PMC